Wealth Enhancement Advisory Services
ABBV icon

Wealth Enhancement Advisory Services’s AbbVie ABBV Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$117M Buy
576,543
+36,002
+7% +$7.75M 0.2% 95
2026
Q1 		$92.7M Sell
540,541
-96,169
-15% -$21.3M 0.19% 102
2025
Q4 		$143M Buy
636,710
+66,720
+12% +$15.2M 0.19% 92
2025
Q3 		$133M Buy
569,990
+15,340
+3% +$3.12M 0.2% 98
2025
Q2 		$105M Buy
554,650
+18,200
+3% +$3.38M 0.17% 116
2025
Q1 		$112M Buy
536,450
+12,085
+2% +$2.35M 0.22% 89
2024
Q4 		$93.2M Sell
524,365
-31,930
-6% -$5.87M 0.18% 115
2024
Q3 		$110M Buy
556,295
+104,454
+23% +$19.5M 0.24% 81
2024
Q2 		$77.5M Buy
451,841
+27,103
+6% +$4.49M 0.18% 110
2024
Q1 		$77.3M Buy
424,738
+32,732
+8% +$5.64M 0.2% 106
2023
Q4 		$60.7M Sell
392,006
-49,324
-11% -$7.19M 0.18% 126
2023
Q3 		$65.8M Buy
441,330
+413,330
+1,476% +$60.7M 0.22% 102
2023
Q2 		$3.77M Sell
28,000
-3,912
-12% -$574K 0.04% 147
2023
Q1 		$5.09M Buy
+31,912
New +$4.88M 0.06% 133
2022
Q4 		– Sell
-44,537
Closed -$6.18M – 317
2022
Q3 		$6.18M Buy
44,537
+30,880
+226% +$4.43M 0.09% 106
2022
Q2 		$2.09M Buy
13,657
+12,072
+762% +$1.84M 0.03% 200
2022
Q1 		$257K Sell
1,585
-317
-17% -$46K ﹤0.01% 294
2021
Q4 		$260K Sell
1,902
-3,546
-65% -$419K ﹤0.01% 280
2021
Q3 		$596K Buy
5,448
+3
+0.1% +$343 0.01% 243
2021
Q2 		$638K Buy
5,445
+119
+2% +$13.4K 0.01% 220
2021
Q1 		$561K Buy
5,326
+504
+10% +$53.9K 0.01% 226
2020
Q4 		$533K Sell
4,822
-34,928
-88% -$3.36M 0.01% 193
2020
Q3 		$3.51M Buy
39,750
+5,036
+15% +$474K 0.09% 79
2020
Q2 		$3.39M Buy
34,714
+605
+2% +$53.3K 0.1% 80
2020
Q1 		$2.82M Buy
+34,109
New +$2.91M 0.1% 88
2019
Q2 		– Sell
-21,343
Closed -$1.68M – 198
2019
Q1 		$1.68M Buy
21,343
+4,833
+29% +$395K 0.09% 90
2018
Q4 		$1.48M Sell
16,510
-17,069
-51% -$1.5M 0.09% 81
2018
Q3 		$2.67M Sell
33,579
-8,579
-20% -$814K 0.16% 46
2018
Q2 		$4.09M Buy
42,158
+34,000
+417% +$3.32M 0.25% 39
2018
Q1 		$752K Buy
8,158
+4,180
+105% +$459K 0.05% 131
2017
Q4 		$399K Buy
+3,978
New +$375K 0.03% 134

Other funds holding ABBV

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
HCM
Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
HPC
HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return
CRM
Cardano Risk Management Rotterdam, Netherlands $13B AUM 49.44% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Wealth Enhancement Advisory Services's ABBV Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its AbbVie (ABBV) stake by 6.7% in Q2 2026, buying an estimated $7.75M and bringing the position to 576,543 shares worth $117M. The position accounts for 0.2% of the portfolio, ranked #95.

Wealth Enhancement Advisory Services first reported a position in ABBV in Q4 2017 and has held it in 31 quarters since. The position peaked at $143M in Q4 2025. 803 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Wealth Enhancement Advisory Services held 576,543 shares of AbbVie worth $117M as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 36,002 AbbVie shares in Q2 2026, an estimated $7.75M.
  • AbbVie made up 0.2% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #95 holding.
  • Wealth Enhancement Advisory Services first reported a position in AbbVie in Q4 2017 and has held it in 31 quarters since.
  • Wealth Enhancement Advisory Services's AbbVie position peaked at $143M in Q4 2025.
  • 803 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.